The FirstTake Podcast – A landmark cancer approval, Pfizer’s Arena deal delivers and the expert view on recent breast cancer developments
Update: 2022-03-24
Description
On this week’s episode editors Virginia Li and Simon King discuss FDA approval of the first novel checkpoint inhibitor for eight years – Bristol Myers Squibb’s LAG-3 inhibitor relatlimab – and evaluate positive data for Pfizer’s etrasimod, which it gained via December’s $6.7 billion acquisition of Arena Pharmaceuticals. In addition, FirstWord’s Michael Flanagan speaks to Adam Brufsky – professor of medicine at the University of Pittsburgh School of Medicine and associate chief for the school’s haematology/oncology division – to discuss the relevance of recent clinical and regulatory events that will impact the treatment of breast cancer.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
